Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients
Completed
Conditions studied: Kidney Transplantation
In brief
This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
Key facts
- Study ID
- NCT01375127
- Run by
- Pfizer
- People needed
- 83
- Starts
- 2011-08-01
- Expected to finish
- 2012-07-01
- Last updated by the study team
- 2013-10-29
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects have discontinued tofacitinib prior to the planned treatment duration in 2 completed Phase 2 studies; or have not enrolled in long-term extension studies.
You may not qualify if…
- No other subjects are eligible for this study
Where it is running
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Palo Alto, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — Stanford, California, United States
- Pfizer Investigational Site — Aurora, Colorado, United States
- Pfizer Investigational Site — Tampa, Florida, United States
- Pfizer Investigational Site — Chicago, Illinois, United States
- Pfizer Investigational Site — Chicago, Illinois, United States
- Pfizer Investigational Site — Boston, Massachusetts, United States
- Pfizer Investigational Site — Springfiled, Massachusetts, United States
- Pfizer Investigational Site — Ann Arbor, Michigan, United States
- Pfizer Investigational Site — Detroit, Michigan, United States
- Pfizer Investigational Site — St Louis, Missouri, United States
- Pfizer Investigational Site — Livingston, New Jersey, United States
- Pfizer Investigational Site — New York, New York, United States
- Pfizer Investigational Site — Valhalla, New York, United States
- Pfizer Investigational Site — Chapel Hill, North Carolina, United States
- Pfizer Investigational Site — Dallas, Texas, United States
- Pfizer Investigational Site — Dallas, Texas, United States
- Pfizer Investigational Site — Fort Worth, Texas, United States
- Pfizer Investigational Site — Richmond, Virginia, United States
- Pfizer Investigational Site — Camperdown, New South Wales, Australia
- Pfizer Investigational Site — Westmead, New South Wales, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.